DIA/FDA Oligonucleotide-based Therapeutics Conference

Featured

Want to learn more about DIA/FDA Oligonucleotide-based Therapeutics Conference? You've come to the right site!

Jim Zisek Director, Global CMC Regulatory Affairs
GlaxoSmithKline, United States
Robert T. Dorsam, PHD Associate Director, Pharmacology/Toxicology, Office of Generic Drugs, CDER
FDA, United States
Daniel Capaldi, PHD Vice President, Analytical and Process Development
Ionis Pharmaceuticals, Inc, United States
Arthur A. Levin, PHD Distinguished Scientist
Avidity Biosciences, United States
Jan Kevin Losos, PHD Director, Safety Assessment Projects
GlaxoSmithKline, United States
Saraswathy V. Nochur, PHD, MSC Chief Regulatory Officer
Alnylam Pharmaceuticals, United States
Ramesh Raghavachari, PHD Supervisor, Unit 3/DPQA IV/OPQA I/OPQ/CDER
FDA, United States
David H. Schubert
United States
Pengfei Song, PHD Senior Clinical Phamacology Reviewer in Oncology, CDER
FDA, United States
James Wild, PHD, MS Pharmacologist, CDER
FDA, United States
Rosanne Seguin, PHD
McGill University, Canada
Scott Henry, PHD Senior Vice President, Nonclinical Development
Ionis Pharmaceuticals, Inc., United States